2020 was a good year for cell and gene therapy (CGT) manufacturers. Financial investment in CGT companies skyrocketed by 200% and the researchers behind CRISPR/ Cas9 brought home a Nobel Prize. As the world gathered courage to face the pandemic, CGT innovators responded by gathering momentum.
Similar momentum was building across the pharma industry. The blistering speed of vaccine research made headlines, but extraordinary breakthroughs were quietly taking place in all corners of the industry. Bold thinking and modern facility designs brought new approaches to facilitating progress.
Of all the positive changes, the following five trends will play a particularly important role in forever changing how we formulate, evaluate and distribute therapies.
